Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation

K. J. Tracey, H. Wei, K. R. Manogue, Y. Fong, D. G. Hesse, H. T. Nguyen, G. C. Kuo, B. Beutler, R. S. Cotran, A. Cerami, S. F. Lowry

Research output: Contribution to journalArticle

599 Citations (Scopus)

Abstract

Cachexia is a potentially lethal syndrome of unknown etiology characterized by anorexia, weight loss, and protein wasting that frequently complicates the treatment of chronic inflammation and cancer. Cachectin/TNF was isolated during the search for a humoral mediator of cachexia and found to stimulate the breakdown of energy stores from adipocytes and myocytes in vitro, but the chronic effects of the monokine in vivo are not known. Sublethal doses of recombinant human cachectin administered twice daily for 7-10 d caused cachexia in rats, as evidenced by reduced food intake, weight loss, and depletion of whole-body lipid and protein stores. Significant anemia is also observed and found to be the result of decreased red blood cell mass, not expanded plasma volume. Leukocytosis and histopathological evidence of tissue injury and inflammation are observed in several organs, including omentum, liver, spleen, and heart. These data suggest that the exposure of the normal host to cachectin is capable of inducing a pathophysiological syndrome of cachexia, anemia, and inflammation similar to that observed during inflammatory states or malignancy.

Original languageEnglish (US)
Pages (from-to)1211-1227
Number of pages17
JournalJournal of Experimental Medicine
Volume167
Issue number3
StatePublished - 1988

Fingerprint

Cachexia
Anemia
Tumor Necrosis Factor-alpha
Inflammation
Weight Loss
Monokines
Erythrocyte Volume
Omentum
Plasma Volume
Leukocytosis
Anorexia
Adipocytes
Muscle Cells
Neoplasms
Proteins
Spleen
Eating
Erythrocytes
Lipids
Liver

ASJC Scopus subject areas

  • Immunology

Cite this

Tracey, K. J., Wei, H., Manogue, K. R., Fong, Y., Hesse, D. G., Nguyen, H. T., ... Lowry, S. F. (1988). Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. Journal of Experimental Medicine, 167(3), 1211-1227.

Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. / Tracey, K. J.; Wei, H.; Manogue, K. R.; Fong, Y.; Hesse, D. G.; Nguyen, H. T.; Kuo, G. C.; Beutler, B.; Cotran, R. S.; Cerami, A.; Lowry, S. F.

In: Journal of Experimental Medicine, Vol. 167, No. 3, 1988, p. 1211-1227.

Research output: Contribution to journalArticle

Tracey, KJ, Wei, H, Manogue, KR, Fong, Y, Hesse, DG, Nguyen, HT, Kuo, GC, Beutler, B, Cotran, RS, Cerami, A & Lowry, SF 1988, 'Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation', Journal of Experimental Medicine, vol. 167, no. 3, pp. 1211-1227.
Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. Journal of Experimental Medicine. 1988;167(3):1211-1227.
Tracey, K. J. ; Wei, H. ; Manogue, K. R. ; Fong, Y. ; Hesse, D. G. ; Nguyen, H. T. ; Kuo, G. C. ; Beutler, B. ; Cotran, R. S. ; Cerami, A. ; Lowry, S. F. / Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. In: Journal of Experimental Medicine. 1988 ; Vol. 167, No. 3. pp. 1211-1227.
@article{ed40f11bf4b74048b2d06fadef735a40,
title = "Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation",
abstract = "Cachexia is a potentially lethal syndrome of unknown etiology characterized by anorexia, weight loss, and protein wasting that frequently complicates the treatment of chronic inflammation and cancer. Cachectin/TNF was isolated during the search for a humoral mediator of cachexia and found to stimulate the breakdown of energy stores from adipocytes and myocytes in vitro, but the chronic effects of the monokine in vivo are not known. Sublethal doses of recombinant human cachectin administered twice daily for 7-10 d caused cachexia in rats, as evidenced by reduced food intake, weight loss, and depletion of whole-body lipid and protein stores. Significant anemia is also observed and found to be the result of decreased red blood cell mass, not expanded plasma volume. Leukocytosis and histopathological evidence of tissue injury and inflammation are observed in several organs, including omentum, liver, spleen, and heart. These data suggest that the exposure of the normal host to cachectin is capable of inducing a pathophysiological syndrome of cachexia, anemia, and inflammation similar to that observed during inflammatory states or malignancy.",
author = "Tracey, {K. J.} and H. Wei and Manogue, {K. R.} and Y. Fong and Hesse, {D. G.} and Nguyen, {H. T.} and Kuo, {G. C.} and B. Beutler and Cotran, {R. S.} and A. Cerami and Lowry, {S. F.}",
year = "1988",
language = "English (US)",
volume = "167",
pages = "1211--1227",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "3",

}

TY - JOUR

T1 - Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation

AU - Tracey, K. J.

AU - Wei, H.

AU - Manogue, K. R.

AU - Fong, Y.

AU - Hesse, D. G.

AU - Nguyen, H. T.

AU - Kuo, G. C.

AU - Beutler, B.

AU - Cotran, R. S.

AU - Cerami, A.

AU - Lowry, S. F.

PY - 1988

Y1 - 1988

N2 - Cachexia is a potentially lethal syndrome of unknown etiology characterized by anorexia, weight loss, and protein wasting that frequently complicates the treatment of chronic inflammation and cancer. Cachectin/TNF was isolated during the search for a humoral mediator of cachexia and found to stimulate the breakdown of energy stores from adipocytes and myocytes in vitro, but the chronic effects of the monokine in vivo are not known. Sublethal doses of recombinant human cachectin administered twice daily for 7-10 d caused cachexia in rats, as evidenced by reduced food intake, weight loss, and depletion of whole-body lipid and protein stores. Significant anemia is also observed and found to be the result of decreased red blood cell mass, not expanded plasma volume. Leukocytosis and histopathological evidence of tissue injury and inflammation are observed in several organs, including omentum, liver, spleen, and heart. These data suggest that the exposure of the normal host to cachectin is capable of inducing a pathophysiological syndrome of cachexia, anemia, and inflammation similar to that observed during inflammatory states or malignancy.

AB - Cachexia is a potentially lethal syndrome of unknown etiology characterized by anorexia, weight loss, and protein wasting that frequently complicates the treatment of chronic inflammation and cancer. Cachectin/TNF was isolated during the search for a humoral mediator of cachexia and found to stimulate the breakdown of energy stores from adipocytes and myocytes in vitro, but the chronic effects of the monokine in vivo are not known. Sublethal doses of recombinant human cachectin administered twice daily for 7-10 d caused cachexia in rats, as evidenced by reduced food intake, weight loss, and depletion of whole-body lipid and protein stores. Significant anemia is also observed and found to be the result of decreased red blood cell mass, not expanded plasma volume. Leukocytosis and histopathological evidence of tissue injury and inflammation are observed in several organs, including omentum, liver, spleen, and heart. These data suggest that the exposure of the normal host to cachectin is capable of inducing a pathophysiological syndrome of cachexia, anemia, and inflammation similar to that observed during inflammatory states or malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0023916786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023916786&partnerID=8YFLogxK

M3 - Article

C2 - 3351436

AN - SCOPUS:0023916786

VL - 167

SP - 1211

EP - 1227

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 3

ER -